Skip to main content

Table 4 Multivariable cox regression model for DFS

From: Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

Gene/Clinical Comparison Adjusted DFS
   HR (95% CI) Wald P-value
CYP2B6 Any variant vs. All WT 1.06 (0.77, 1.46) 0.72
CYP2C9 Any variant vs. All WT 1.11 (0.80, 1.53) 0.53
CYP2D6 G/A vs. A/A 0.94 (0.46, 1.94) 0.87
  G/G vs. A/A 0.99 (0.50, 1.99) 0.99
CYP3A4 *1B/*1A vs. *1A/*1A 2.79 (1.52, 5.14) 0.001
  *1B/*1B vs *1A/*1A 2.67 (0.86, 8.34) 0.09
CYP3A5 *3/*1 vs. *1/*1 1.18 (0.47, 2.98) 0.72
  *3/*3 vs. *1/*1 2.09 (0.79, 5.50) 0.14
CYP3A5 *6/*1 vs. *1/*1 1.37 (0.39, 4.79) 0.62
GSTM1 Null vs. Non-null 0.78 (0.57, 1.06) 0.12
GSTT1 Null vs. Non-null 1.32 (0.86, 2.01) 0.21
GSTP1 Any Var vs. All WT 0.94 (0.69, 1.28) 0.69
Lymph node Continuous 1.02 (1.00, 1.04) 0.03
Tumor size Continuous 1.00 (0.97, 1.01) 0.46
Age Continuous 0.99 (0.97, 1.01) 0.46
ER Pos vs. Neg -- --
PR Pos vs. Neg 1.01 (0.69, 1.50) 0.95
Race Black vs. White 1.08 (0.52, 2.25) 0.84
  Other vs. White 1.84 (0.91, 3.70) 0.09
Arm CAF+HDC vs. CAF 0.66 (0.48, 0.91) 0.01
  1. CAF: cyclophosphamide, doxorubicin, fluorouracil; DFS: disease free survival; ER: estrogen receptor; HDC: high dose chemotherapy; HR: hazard ratio; PR: progesterone receptor